Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast CancerHeikki Joensuu, Henrik Lindman, Johan Ahlgren et al.|Cancer Research|2010Cited by 14
Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)Heikki Joensuu, Henrik Lindman, Jennifer A. Fraser et al.|Cancer Research|2018Cited by 12
Abstract PD01-02: Integration of Capecitabine into Anthracycline-and Taxane-Based Adjuvant Therapy for Triple-Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX StudyHenrik Lindman, Heikki Joensuu, Peter Bono et al.|Cancer Research|2010Cited by 6